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Objective: To compare the use of polypropylene mesh (PM) and the traditional anterior vagi-
nal wall colporraphy in women with anterior vaginal wall prolapse (AVWP) using objective 
and subjective tests and evaluation of quality of life (QoL).
Materials and Methods: One hundred women were randomly distributed in two preopera-
tory groups. The first group (mesh) (n = 45) received a PM implant and the control group 
(n = 55) was submitted to traditional colporraphy. Postoperatory follow-up was done after 
12 months. The primary objective was the correction of the Ba point ≤ -2 POP-Q (Pelvic 
Organ Prolapse Quantification System) and the secondary objective was the improvement 
of vaginal symptoms and QoL through ICIQ-VS (International Consultation on Incontinence 
Questionnaire - Vaginal Symptoms). Complications related to the use of PM or not were also 
described.
Results: There was a significant difference between all POP-Q measures of pre- and postope-
ratory periods of each group in particular. There was a significant difference of the Ba point 
of the postoperatory period between the Mesh and Control group. The mean of Ba point in 
the Mesh group was statistically lower than of the Control group, depicting the better ana-
tomical result of the first group. Both techniques improved vaginal symptoms and QoL. The 
most frequent complication of the Mesh group was prepubic hematoma in the perioperative 
period. In 9.3% of the cases treated with mesh it was observed PM exposition at the anterior 
vaginal wall after 12 months, being most of them treated clinically.
Conclusion: The treatment of AVWP significantly improved the Ba point in the Mesh group 
in comparison to the Control group. There were no differences of the vaginal symptoms and 
QoL between the two groups after 12 months. There were few and low grade complications 
on both groups.
INTRODuCTION
There are many published studies in the li-
terature on association of the aging process and 
prevalence of female pelvic floor diseases, such as 
genital prolapses and urinary incontinence. Pel-
vic organ prolapses (POP) are prevalent conditions 
and affect 30% of childbearing women (1-4). The 
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causes of POP are not clear, but normal delivery 
seems to be the primary etiologic factor. In the 
Brazilian population, the independent risk factors 
for POP are vaginal delivery, a large fetus and fa-
mily history of POP (5).
 Many surgical techniques have been pro-
posed to correct POP. However, the published 
results are not completely satisfactory or homo-
geneous. For example, the success rates of tra-
ditional anterior colporraphy to correct anterior 
vaginal wall prolapse vary from 37 to 100% (6).
 The present study was proposed to evalua-
te women with AVWP treated with anterior tradi-
tional colporraphy using PM or not, with objective 
and subjective tests and QoL impact.
MATERIALS AND METhODS
Study Design and Objectives
 This is a prospective, randomized, single-
-blinded and controlled study to evaluate the ou-
tcomes of two surgical procedures to correct AVWP. 
Urinary symptoms such as urgency and stress uri-
nary incontinence (SUI) will be addressed in another 
study (Part II).
Patients, study location and eligibility criteria
 From February 2008 to December 2010, 122 
women attending the Ambulatory of Urogynecolo-
gy, Health Secretary of Jau, SP, Brazil, were selected. 
Women 45 years old or older, with AVWP ≥ II (POP-
-Q Stage) (7) without previous surgical correction or 
with previous surgical treatment of AVWP without 
the use of PM were selected. The criteria of exclusion 
or included: women who were previously treated 
(due to AVWP or SUI) using PM, who were receiving 
oncological treatment, with altered Papanicolau 
Smear exam or with uterine bleeding, with genital or 
acute urinary infection, patients who didn’t commit 
to ambulatory follow-up or that refused the written 
informed consent.
Diagnosis and data collection
 Methods, definitions and units were used 
according to the standards of the International Con-
tinence Society (ICS) and International Urogynecolo-
gy Association (IUGA) (8). Data included age (years), 
parity, number of deliveries, body mass index (BMI 
- Kg/m2), hormonal status (pre-, peri and postmeno-
pausal), history of previous histerectomy (yes or no) 
and POP stage (POP-Q). Clinical categories were used 
to evaluate the hormonal status. Women with more 
than 12 months of amenorrhea were considered in 
the postmenopausal period. The study was approved 
by the Ethical Committee of the Federal University of 
Sao Paulo under the number 1335/08.
 The same group of authors idealized, deve-
loped and conducted all steps of the study, including 
follow-up. PM supplies did not donate funds or sur-
gical devices samples for the study.
Evaluations
 Objective:
  POP-Q was used to measure (centi-
meters) the supporter of several anatomical aspects 
of the vaginal canal (7);
 Subjective:
  ICIQ-VS: This is a translated and 
validated questionnaire for Portuguese  (9) used to 
evaluate several pelvic floor dysfunctions inclu-
ding questions regarding intestinal, vaginal, sexual 
symptoms and QoL impact. It includes 14 questions 
divided into three independent domains. Vaginal 
symptoms score (VSS) varies from 0 to 53. Sexual 
symptoms score (SSS) varies from 0 to 58 and QoL 
impact score varies from 0 to 10. Usually each ques-
tion has 3 to 5 possible answers; the higher the score, 
the most severe is the symptom or the negative QoL 
impact.
 Safety evaluation related to the use (or 
not) of PM implant
 The specific complications related to the PM 
implant were described and standardized by ICS/
IUGA in order to define adequately the status of the 
disease caused by the complication of its use (10).
Objectives
 Primary – POP evaluation using Ba Point ≤ 
-2 (POP-Q) and POP-Q stages (0 and 1) after 12-mon-
th follow-up.
 Secondary – vaginal symptoms and QoL im-
pact evaluation using the ICIQ-VS scores (VSS and 
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QoL) and surgical complication by means the ICS/
IUGA international code after 12-month follow-up.
Polypropylene mesh kit description
NAZCA TC KIT (Promedon, Cordoba, Argentina)
NAZCA TC kit includes type 1 PM, monofi-
lament, with macropores varying from 0.5 to 1 mm 
diameter and density of 60.5 g/m2. PM body contains 
6 mm diameter holes in order to facilitate integration 
with host tissue, lowering the amount of synthetic 
implanted material and local inflammatory reaction. 
Four self-adjustable tapes of the same material arise 
from the body, ending in needle connectors. Two of 
these tapes are passed through prepubic insertion of 
the needles (vaginal suprapubic route) and the other 
two (posterior) are passed by the needles through 
transobturator route. The needles reach the tendi-
neous arcs, close to the ischial spines bilaterally (11).
Surgical procedure
 All surgeries were performed under spinal 
anesthesia and all patients received 2g of IV cepha-
zolin for prophylaxis. Bladder catheter was inserted 
in the beginning of the surgery and removed in the 
first postoperatory day. As needed, concurrent pro-
cedures were performed, such as posterior colporra-
phy and vaginal hysterectomy. Patients of the con-
trol group with urodynamic diagnosis of SUI were 
concurrently treated with retropubic synthetic sling. 
All patients were operated by the same surgical team 
(JTNT, MMMT). Before the beginning of the study, 
the surgeons performed two surgeries using polypro-
pylene mesh kit in order to reduce the learning curve 
impact on the final results.
NAZCA TC surgical procedure
 With the patient in the lithotomy position, a 
midline incision in the anterior vaginal wall is per-
formed, from the midurethra to the uterine cervix. 
The dissection is continued until the ischial-pubic 
branch and inferior edge of the pubic symphysis. The 
needles are passed from the vaginal incision to the 
suprapubic region in order to allocate the prepubic 
tapes. After removing the handle of the needle on 
the vaginal side, it is reconnected on the suprapubic 
side of the needle. After the anterior tape of the NA-
ZCA TC is connected, the needle is gently pulled and 
the maneuver is finished with the exteriorization of 
the anterior tape in the suprapubic region. The same 
maneuver is made in the other side, creating a bra-
cket of the median urethra. The transobturator ne-
edle is passed through the genitofemoral fold 2 cm 
laterally and 3 cm inferiorly to the urethral meatus. 
This needle must reach the region close to the ischial 
spine, exteriorized through the vaginal incision. The 
posterior tapes are connected to the needle and re-
moved, exteriorizing through the genitofemoral fold 
incision. This maneuver is repeated in the contrala-
teral side. The body of the mesh is fixed with absor-
bable sutures in the region of the cardinal ligaments 
and in the region of the cervical ring. The four tapes 
are adjusted in order to correct AVWP without folds 
or material redundancy. The excess is discharged be-
fore the closure of the anterior vaginal wall incision, 
performed with separated sutures of Vycril 2-0 (11).
Traditional anterior colporraphy
 With the patient in the lithotomy position, 
a midline incision on the anterior vaginal wall is 
performed, from the midurethra to the uterine cer-
vix. The anterior vaginal wall is separated from the 
vesicovaginal fascia and from the bladder using 
pointless detachment. This maneuver identifies oc-
casional lesion (relaxation or rupture) of the vesico-
vaginal fascia. In case of central defect it is corrected 
using plication of the fascia along the midline using 
separated sutures of Vycril 2-0. Lateral defects are 
treated using localized sutures with Vycril 2-0 (12).
Statistical analysis
In order to evaluate preoperatory differen-
ces between both groups, chi-square test was used 
for cathegoric variables and t-Student test for conti-
nuous variables with normal distribution. All nume-
rical data were expressed as mean ± standard devia-
tion (SD). Paired t-test was used to detect differences 
between pre- and postoperatory periods. The signifi-
cance level adopted was 5%.
 
Sample size calculation
The sample size was estimated upon litera-
ture data (6,12). It was expected anatomical failure 
after 12-month follow-up of 38% for control group 
and 12% for mesh group. In order to detect this di-
fference (bilateral test), with 0.05 level of significan-
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ce and power of the test 80%, 42 women should be 
allocated at least in each group. With an estimate 
of 10% loss after 12-month follow-up, a total of 92 
women were randomized. The sample was increased 
to 100 women in order to consider a 20% loss of 
follow-up after 24 months.
Randomization and blinding
This trial adopted single-blind masking to re-
duce bias derived from the knowledge of the patients 
about which procedure she was submitted. 
Randomization based in a single sequence 
of random tasks is called simple randomization. This 
technique maintains complete randomization of a 
single subject in a determined group, with adequate 
balance, mainly in groups with more than 100 indivi-
duals (13). Randomization was made by simple raffle 
few minutes before surgery when the result was in-
formed to the surgical team, in order to proceed with 
the designed surgery.
 Women were randomly distributed in two 
groups: Mesh group (M) (n = 45) that used PM im-
plant and Control group (C) (n = 55), treated with 
traditional anterior colporraphy.
Figure-1 shows details of patient selection, 
including randomization and the final number of 
evaluated patients after 12-month follow-up in 
both groups.
INITIAL SELECTION (n = 122)
MESH Group (n = 45) Control Group (n = 55) 
EXCLUDED (n = 22) 
 Non eligible(n = 15) 
 Refused participation (n = 7) 
RANDOMIZATION (n = 100) 
Not evaluated (n = 2) Not analyzed (n = 1) 
 Death unrelated to the study (n = 1)  Lost follow-up (n = 1) 
 Cerebral hemorrhage (n = 1) 
MESH GROUP 
(n = 43) 
EVALUATION AFTER 1 YEAR OF FOLLOW-UP 
CONTROL GROUP 
(n = 54) 
Figure 1 - Patient flow chart, randomization and group allocation.
 INITIAL SEL ION (n = 122) 
 RANDOMI TION (n = 100) 
 ME h roup (n = 45) 
 MESh OuP
  43) 
CONTROL G uP
(n = 54)
 Control Group (n = 55) 
 EXCLuDED (n = 22) 
t analyzed (n = 1)ot evaluated (n = 2)
•	 Non eligible (  = 15) 
•	 Refused participation (n = 7) 
•	 Lost follow-up (n = 1)•	 Death unrelated to the study (n = 1)•	 Cerebral hemorrhage (n = 1)
EVALuATION AFTER 1 YEAR OF FOLLOW-uP
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 Concurrent surgeries were performed accor-
ding patient’s individual needs. Postoperatory eva-
luation was performed after 12 months of surgery. 
The informed consent was read and signed by all 
patients before the beginning of the study.
RESuLTS
During the preoperatory period, both groups 
were homogeneous regarding age, parity, number 
of deliveries, BMI, hormonal status, previous hys-
terectomy and POP stage, indicating an adequa-
te randomization effect (Table-1). Table-2 shows 
the pre- and postoperatory POP-Q measures. Both 
groups were also homogeneous according to these 
variables, since there was no significant statistical 
difference of all POP-Q measures between groups 
in the preoperatory period. There was a statistical 
significant difference in all POP-Q values between 
the pre- and postoperatory period in each particu-
lar group, demonstrating that both techniques were 
able to improve anatomical parameters. However, 
according to the established cure criteria (Ba Point 
≤ -2) there was a statistical significant difference 
of Aa and Bb measures (POP-Q) in the postopera-
tory period between groups Control and Mesh. Bb 
means in the preoperatory period were + 3.38 in 
Mesh group and + 2.55 in Control group (p = 0.10). 
Measures for the same point at the postoperatory 
period were -2.46 for Mesh group and -1.57 for 
Control group (p < 0.0001) (Table-2). According to 
the POP-Q stage classification, 36/43 (83.7%) pa-
tients of Mesh group and 30/53 (55.5%) patients of 
Control group were considered cured (Stages 0 and 
I) after 12-month follow-up and this difference was 
considered statistically significant (p = 0.006) (Ta-
ble-3). Absolute risk reduction (ARR) was 28% and 
the number needed to treat (NNT) was 4. In regard 
to the subjective data, there was no difference be-
tween groups during preoperatory period for VSS 
and QoL impact. Due to the low sexual activity in 
both groups Sexual Symptoms Score (SSS) was not 
calculated. However, we observed that both surgical 
procedures improved VSS and QoL impact (Table-4). 
Table-5 shows the concurrent surgical procedures in 
both groups. They were homogeneous in relation to 
this variable, and there was no significant statistical 
difference between groups. Table-6 shows the safety 
profile of the procedures through analysis of com-
plications during the intra, peri- and postoperatory 
periods after 12 months.
DISCuSSION
According to recent published data, the use of 
PM for correction of POP is controversial. It has been 
described outcomes of different available meshes in 
the market, presented as kits (6,11) or in a standard 
size and molded according to surgeon’s preference 
during surgery (12,14).
 Polypropylene mesh to correct POP was first 
described in 1998 (15) and, since then, its use became 
popular (16). Recently the Food and Drug Adminis-
tration (FDA) evaluated the efficacy and safety of the 
use of PM in POP corrective surgeries in a systematic 
review study from 1996 to 2011. It was observed that 
the use of PM to correct AVWP reduces the risk of 
POP recurrence. However, this anatomical improve-
ment could not be related to better functional results 
or improvement on QoL (17).
 In general, results from our study are in 
accordance to this systematic review. The Mesh 
group showed better anatomical improvement of 
AVWP in relation to the Control group. Differen-
tly to the referred review, we have observed that 
both groups showed a significant improvement of 
the vaginal symptoms and QoL impact, what is 
in accordance to the results presented by Palma 
et al. These authors evaluated 104 women treated 
with NAZCA TC in an international multicentric 
study (11). Another trial with similar outcomes 
was published by Nguyen and Burchette (18). 
They studied 76 patients with AVWP treated by 
anterior colporraphy with or without use of PM 
in a randomized controlled study. It was obser-
ved success rate of 55% of the anterior colpor-
raphy group versus 87% of the mesh group, but 
both groups showed improvement of urinary and 
POP symptoms. Delroy et al. (19) in a prospective, 
controlled and randomized trial treated women 
with AVWP using the same kit of the present stu-
dy and showed an anatomical success (Point Ba < 
-1) in 82.5% in group Mesh and 56.4% in Control 
group at 12-month follow-up. The NNT was 4. In 
both groups it was observed improvement of POP 
symptoms and QoL impact. Most data presented in 
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Table 1 - Demographic characteristics of the Mesh and Control groups during preoperatory period (n=100)
Demographic characteristics
Mesh
(n = 45)
Control
(n = 55)
p-value
Age (years)
Mean (SP) 66.8 (9.2) 63.4 (9.5) 0.08*
Interval (min/max) 53-84 48-84
Parity
Nulliparous n (%) 0 (0) 3 (5.5) 0.94*
Multiparous n (%) 45 (100) 52 (94.5)
Number of deliveries
Mean (SD) 4.2 (2.6) 4.2 (2.7) 0.94*
Interval (min/max) 1-14 0-12
BMI (kg/m2)
Mean (SD) 27.5 (5.4) 27.8 (4.9) 0.76*
Interval (min/max) 17-42 16-39
hormonal status
Pre-menopausal (%) 2 (4.4) 0 (0) 0.86**
Per-menopausal (%) 0 (0) 1 (0.2)
Post-menopausal (%) 43 (95.6) 54 (99.8)
Previous hysterectomy
Yes (%) 3 (6.7) 6 (10.9) 0.41**
No (%) 42 (93.3) 49 (89.1)
POP stage (POP-q)
II (%) 10 (22.2) 19 (34.5) 0.32**
III (%) 28 (62.2) 31 (56.4)
IV (%) 7 (15.6) 5 (9.1)
Values showed as mean ± standard deviation (SD), interval (Minimum/Maximum), number of patients (n) or percentage (%)
* Student t test for independent samples
** Qui-square test
this study is similar to ours, including cure rates 
for both groups and NNT.
 Due to a rise of complication rates in the 
literature, FDA instructed surgeons to cautiously 
use PM for AVWP (20). Complications were cate-
gorized and classified according to ICS/IUGA (10). 
In the present study there were only minor com-
plications with no life risk of any patients. During 
the peroperatory period it was observed 8 patients 
(18%) of the Mesh group with prepubic hemato-
ma secondary to the needle passage that did not 
required surgical intervention and that resolved 
spontaneously. It was observed urinary retention 
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Table 2 - POP-q measurements in centimeters ± standard deviation (SD) at pre- and postoperatory periods from Mesh and Control groups
Mesh Control pa
Aa
Pre-op 1.47 (1.61) 1.38 (1.78) 0.81
Post-op -2.39 (0.82) -1.59 (1.01) < 0.0001
pb < 0.0001 < 0.0001
Ba
Pre-op 3.38 (2.50) 2.55 (2.50) 0.10
Post-op -2.46 (0.70) -1.57 (1.04) < 0.0001
pb < 0.0001 < 0.0001
C
Pre-op -1.44 (5.10) -1.56 (4.90) 0.90
Post-op -6.44 (1.14) -6.70 (1.34) 0.32
pb < 0.0001 < 0.0001
D
Pre-op -2.78 (5.54) -3.80 (4.89) 0.36
Post-op -7.6 (0.66) -7.8 (1.30) 0.84
pb 0.0006c < 0.0001
Ap
Pre-op -0.58 (1.87) -0.67 (1.97) 0.81
Post-op -2.74 (0.66) -2.67 (1.34) 0.74
pb < 0.0001 < 0.0001
Bp
Pre-op 0.42 (3.33) 0.18 (2.90) 0.70
Post-op -2.74 (0.66) -2.79 (0.53) 0.69
pb < 0.0001 < 0.0001
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Table 3 - Cure rates according POP stage (POP-q). Results presented in frequency and percentage.
POP stage Mesh (n = 43) Control (n = 53) p*
0-I** 36 (83.7%) 30 (55.5%) 0.006
II 7 (16.3%) 24 (44.5%)
III - -
IV - -
TOTAL 43 (100%) 53 (100%)
* Student t-test for independent samples
** Objective cure of POP was defined as Stage POP-Q < II after 12-month follow-up.
Gh (genital hiatus)
Pre-op 4.70 (1.10) 4.80 (1.30) 0.65
Post-op 2.63 (0.69) 2.76 (0.64) 0.34
pb < 0.0001 < 0.0001
PB (perineal body)
Pre-op 2.70 (0.84) 2.70 (0.77) 0.71
Post-op 4.00 (0.62) 4.04 (0.77) 0.80
pb < 0.0001 < 0.0001
TVL (total vaginal length)
Pre-op 9.35 (1.04) 9.40 (1.03) 0.81
Post-op 8.23 (0.87) 8.69 (1.47) 0.08
pb < 0.0001 < 0.0001
POP-q = Pelvic Organ Prolapse Quantification
a Student t test for independent samples 
b Student t test for paired samples
c Student t test for paired samples (analysis of patients with point D after the surgery) 
c o n t i n u a t i o n
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Table 4 - VSS and qoL scores (ICIq-VS) at the pre- and postoperatory periods from Mesh and  Control groups. Values presented as 
mean ± standard deviation (SD).
Mesh Control pa
VSS (interval 0-53)
Preop 25.05 (9.5) 23.6 (10.4) 0.47
Postop 3.24 (4.7) 4.02 (4.4) 0.40
pb < 0.0001 <0.0001
QoL (interval 0-10)
Preop 8.51 (2.32) 8.45 (2.56) 0.91
Postop 0.14 (0.67) 1.13 (2.9) 0.03
pb < 0.0001 < 0.0001
VSS = Vaginal Score Symptoms
qoL = Quality of Life score
a t Student test for independent samples
b t Student test for paired samples
Table 5 - Concurrent surgical procedures in Mesh (n = 45) and Control (n = 55) groups. Values represent the number of patients 
according to the type of surgery in each group and respective percentage.
Concurrent surgical procedures
MESH
n (%)
CONTROL
n (%)
p*
Posterior colporraphy 17 (37.8) 22 (40) 0.98
Vaginal hysterectomy 17 (37.8) 24 (43.6) 0.69
Retropubic synthetic sling - 14 (25.5) -
* Student t test for independent samples
during the first postoperatory period secondary to 
an infravesical obstruction due to the synthetic 
sling (control group) or due to the prepubic arms 
of the NAZCA TC. In three cases of the Mesh group 
(6.3%) and two cases of the Control group (3.7%) 
it was necessary to readjust the suburethral mesh, 
promoting its relaxation in the first day of posto-
peratory with complete resolution of the obstruc-
tive symptoms. After 12-month follow-up it was 
observed mesh exposition < 1 cm diameter on the 
anterior vaginal wall in four patients (9.3%). Three 
patients were treated with a topic estrogen cream 
and sexual abstinence with good results. Only one 
patient (2.3%) was submitted to partial resection of 
the exposed mesh and primary suture of the vaginal 
margins. These data are in accordance to the litera-
ture, that range from 5 to 15% (17,19,21,22).
 The main limit of the present study was that 
it was performed in a single center and did not have 
an independent examiner during objective evalua-
tions at the postoperatory period. Another point to be 
discussed is the randomization technique. Although 
a different number of women were assigned to each 
group, it did not alter the homogeneity of groups 
regarding sociodemographic, clinical and gynecolo-
gical variables (POP-Q), allowing correct comparison 
of both groups (13). 97% of patients were evaluated 
at 12-month follow-up signaling low rate of patient 
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loss. This was one of the most significant aspects of 
the present study along with its design.
 Finally, some authors advocate that the 
use of PM through the vaginal route is associated 
with low complication and POP recurrence rates. 
Nevertheless, after clarification, surgeons should 
help patients to decide on whether she takes the 
risk of some complications – such as mesh exposi-
tion – or face the risk of probable POP recurrence 
in the future (23).
CONCLuSIONS
The treatment of AVWP significantly impro-
ved the Ba point in the Mesh group in comparison 
to the Control group. There were no differences of 
the vaginal symptoms and QoL impact between the 
two groups after 12 months. There were few and low 
grade complications on both groups.
ABBREVIATIONS
POP = Pelvic organ prolapse 
AVWP = Anterior vaginal wall prolapse
PM = Polypropylene mesh
SUI = Stress urinary incontinence
POP-Q = Pelvic Organ Prolapse Quantification
ICS = International Continence Society
IUGA = International Urogynecology Association
BMI = Body mass index
ICIQ-VS = International Consultation on Inconti-
nence Questionnaire - Vaginal Symptoms
VSS = Vaginal symptoms score
SSS = Sexual symptoms score
Table 6 - Safety according to the reported complication rates and to the standardized codes of the International Continence Society 
and International urogynecology Association at intra, peri and postoperatory periods after 12-month follow-up of Mesh (M) (n = 43) 
and Control (C) (n = 54) groups.
COMPLICATIONS
Intra and periopera-
tory follow-up
Two-month follow-
-up
12-month follow-up
ICS / IUGA Code 
(M)M
n (%)
C
n (%)
M
n (%)
C
n (%)
M
n (%)
C
n (%)
Bleeding
( < 500 mL)
1
(2.3)
1
(1.8)
- - - - 7AT1S1
Prepubic hematoma
8
(18.6)
- - - - - 7AT1S1
Slight inguinal pain - -
5
(11.6)
- - - 6BT2S1
Urinary retention with relaxation of 
the suburethral PM
3
(7)
2
(3.7)
- - - - 4BT1S1
Mesh exposition in the anterior 
vaginal wall
- - - -
4
(9.3)
- 2BT3S1
Dispareunia - - - -
1
(2.3)
- 1BT3S1
ICS = International Continence Society
IuGA = International Urogynecology Association
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QoL = Quality of life
M = Mesh group
C = Control group
SD = Standard deviation
FDA = Food and Drug Administration
ARR = Absolute risk reduction
NNT = Number needed to treat
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